ZNF433 and nonpapillary renal cell carcinoma: Though additional large-scale validation is warranted, we anticipate that assessing ZNF433 mRNA expression in biopsies will be most beneficial as a diagnostic tool for screening and identifying patients at higher risks of developing the aggressive ccRCC subtypes.